Cardiovascular and Renal Endpoints With Flozins - an Observational Prospective Study in CKD HFpEF Patients

The main aim of this study is to holistically assess the cardiovascular and renal outcomes in HFpEF CKD patients with and without SGLT2 inhibition, with focus on the endothelial disfunction, MACE and mortality using clinical evaluation, flow mediated dilatation, carotid-femoral pulse wave velocity, intima-media thickness, echocardiographic parameters, NMR metabolomics and a series of novel biomarkers.

NCT Number	NCT07237451
Lead Sponsor	Grigore T. Popa University of Medicine and Pharmacy Collaborators: Dr. C.I. Parhon Hospital, Iasi, The Executive Agency for Higher Education, Research, Development and Innovation Funding
Conditions	CKD - Chronic Kidney Disease, Heart Failure Preserved Ejection Fraction, SGLT2 Inhibitors, Diabetes (DM)
Enrollment	200 participants
Start Date	2025-01-08
Primary Completion	2027-03-01 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-11-19